We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-0.95%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$55.7B
AUM Growth
+$1.33B
Cap. Flow
+$2.27B
Cap. Flow %
4.08%
Top 10 Hldgs %
19.71%
Holding
3,688
New
269
Increased
1,855
Reduced
1,236
Closed
227

Sector Composition

Rank Sector Weight
1 Technology 10.05%
2 Financials 9.3%
3 Healthcare 7.74%
4 Industrials 6.94%
5 Communication Services 5.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ICLN icon
3251
iShares Global Clean Energy ETF
ICLN
$2.08B
$96K ﹤0.01%
+10,045
New +$95K
UAN icon
3252
CVR Partners
UAN
$1.24B
$96K ﹤0.01%
2,948
-50
-2% -$1.75K
GNMK
3253
DELISTED
GenMark Diagnostics, Inc
GNMK
$95K ﹤0.01%
17,550
+4,300
+32% +$21.4K
DF
3254
DELISTED
Dean Foods Company
DF
$94K ﹤0.01%
10,861
+291
+3% +$2.87K
FMSA
3255
DELISTED
Fairmount Santrol Holdings Inc.
FMSA
$92K ﹤0.01%
21,651
+1,568
+8% +$7.88K
RNGR icon
3256
Ranger Energy Services
RNGR
$388M
$90K ﹤0.01%
11,100
+900
+9% +$8.38K
MXWL
3257
DELISTED
Maxwell Technologies Inc
MXWL
$90K ﹤0.01%
15,240
+1,200
+9% +$6.98K
ACTG icon
3258
Acacia Research
ACTG
$465M
$88K ﹤0.01%
25,140
+1,400
+6% +$5.13K
VSTM icon
3259
Verastem
VSTM
$615M
$88K ﹤0.01%
2,457
-2,234
-48% -$86.5K
CRD.A icon
3260
Crawford & Co Class A
CRD.A
$642M
$87K ﹤0.01%
10,817
-96
-0.9% -$803
DEST
3261
DELISTED
Destination Maternity Corporation
DEST
$87K ﹤0.01%
+33,600
New +$81.3K
PGLC
3262
DELISTED
Pershing Gold Corporation. Common Stock
PGLC
$87K ﹤0.01%
42,222
-750
-2% -$1.66K
AMSC icon
3263
American Superconductor
AMSC
$1.5B
$85K ﹤0.01%
14,547
+2,000
+16% +$10.3K
TCRT icon
3264
Alaunos Therapeutics
TCRT
$4.84M
$85K ﹤0.01%
145
DHX icon
3265
DHI Group
DHX
$158M
$84K ﹤0.01%
52,195
+14,680
+39% +$26K
STB
3266
DELISTED
Student Transportation Inc
STB
$84K ﹤0.01%
11,166
-24,889
-69% -$164K
EAD
3267
Allspring Income Opportunities Fund
EAD
$378M
$83K ﹤0.01%
10,376
-1,565
-13% -$12.9K
BRN icon
3268
Barnwell Industries
BRN
$13.8M
$81K ﹤0.01%
43,380
HERZ
3269
Herzfeld Credit Income Fund
HERZ
$32.3M
$80K ﹤0.01%
1,438
-240
-14% -$13.5K
DWSN icon
3270
Dawson Geophysical
DWSN
$131M
$80K ﹤0.01%
+12,414
New +$72.8K
VOC icon
3271
VOC Energy
VOC
$54.1M
$80K ﹤0.01%
19,548
-2,974
-13% -$15.5K
CCL icon
3272
CALL
Carnival Corporation Ltd
CCL
$38B
$79K ﹤0.01%
139,400
-28,200
-17% -$1.92M
TEUM
3273
DELISTED
Pareteum Corporation
TEUM
$78K ﹤0.01%
+31,932
New +$77.1K
III icon
3274
Information Services Group
III
$251M
$73K ﹤0.01%
17,362
SPY icon
3275
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
$72K ﹤0.01%
25,700
+1,400
+6% +$382K

Similar funds

Raymond James & Associates's Q1 2018 Portfolio in Review

As of Q1 2018, Raymond James & Associates held 3,688 positions worth $55.7B, up 2.4% from $54.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Raymond James & Associates deployed $2.27B of net new capital in Q1 2018, opening 269 new positions and adding to 1,855 existing holdings. Its largest new stake was Nutrien: 608,282 shares worth $28.7M.

By sector, the portfolio is most concentrated in Technology at 10% of assets, up from 9.7% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was AbbVie, an estimated $68.1M trimmed.

  • Raymond James & Associates's largest Q1 2018 buy was Nutrien: 608,282 shares worth $28.7M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q1 2018, an estimated $211M increase.
  • Raymond James & Associates's biggest Q1 2018 reduction was AbbVie, cutting an estimated $68.1M.
  • Raymond James & Associates fully exited Regal Entertainment Group in Q1 2018, selling an estimated $48.4M.
  • Raymond James & Associates's ten largest holdings make up 20% of its $55.7B portfolio in Q1 2018.
  • Raymond James & Associates opened 269 new positions and closed 227 in Q1 2018.
  • Raymond James & Associates's portfolio value rose 2.4% quarter-over-quarter to $55.7B.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.